A detailed agenda for all Shockwave Medical symposia and featured presentations can be found here. While under clinical investigation in the COSIRA-II trial (U.S. and Canada), the Reducer is CE-marked ...
SANTA CLARA, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified ...
Shockwave C2+ Catheter Expands Utility of IVL in Calcified Coronary Arteries Shockwave C2+ is commercially available for the treatment of de novo coronary artery disease in Europe and select other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results